Iovance Biotherapeutics Stock Probability of Future Stock Price Finishing Over 9.07
| IOVA Stock | USD 8.58 0.01 0.12% |
Closest to current price Iovance long CALL Option Payoff at Expiration
Iovance |
Iovance Biotherapeutics Target Price Odds to finish over 9.07
The tendency of Iovance Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 9.07 or more in 90 days |
| 8.58 | 90 days | 9.07 | about 76.34 |
Based on a normal probability distribution, the odds of Iovance Biotherapeutics to move over $ 9.07 or more in 90 days from now is about 76.34 (This Iovance Biotherapeutics probability density function shows the probability of Iovance Stock to fall within a particular range of prices over 90 days) . Probability of Iovance Biotherapeutics price to stay between its current price of $ 8.58 and $ 9.07 at the end of the 90-day period is about 13.09 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.17 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Iovance Biotherapeutics will likely underperform. Additionally Iovance Biotherapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Iovance Biotherapeutics Price Density |
| Price |
Predictive Modules for Iovance Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Iovance Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Iovance Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Iovance Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Iovance Biotherapeutics is not an exception. The market had few large corrections towards the Iovance Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Iovance Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Iovance Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | 2.17 | |
σ | Overall volatility | 0.92 | |
Ir | Information ratio | -0.05 |
Iovance Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Iovance Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Iovance Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Iovance Biotherapeutics generated a negative expected return over the last 90 days | |
| Iovance Biotherapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.19 M. Net Loss for the year was (444.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash with (361.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a very weak financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer |
Iovance Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Iovance Stock often depends not only on the future outlook of the current and potential Iovance Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Iovance Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 235.1 M | |
| Cash And Short Term Investments | 279.9 M |
Iovance Biotherapeutics Technical Analysis
Iovance Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Iovance Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Iovance Biotherapeutics. In general, you should focus on analyzing Iovance Stock price patterns and their correlations with different microeconomic environments and drivers.
Iovance Biotherapeutics Predictive Forecast Models
Iovance Biotherapeutics' time-series forecasting models is one of many Iovance Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Iovance Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Iovance Biotherapeutics
Checking the ongoing alerts about Iovance Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Iovance Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Iovance Biotherapeutics generated a negative expected return over the last 90 days | |
| Iovance Biotherapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.19 M. Net Loss for the year was (444.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash with (361.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a very weak financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer |
Check out Iovance Biotherapeutics Backtesting, Iovance Biotherapeutics Valuation, Iovance Biotherapeutics Correlation, Iovance Biotherapeutics Hype Analysis, Iovance Biotherapeutics Volatility, Iovance Biotherapeutics History as well as Iovance Biotherapeutics Performance. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.29) | Return On Equity (0.57) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.